Results 31 to 40 of about 12,281 (206)

Refractory gout in primary myelofibrosis [PDF]

open access: yesBlood, 2019
![Figure][1] A 66-year-old man from the Dominican Republic presented to the Myeloproliferative Neoplasms Clinic at Mount Sinai with a 10-year history of untreated JAK2V617F- positive primary myelofibrosis (PMF).
Sangeetha Venugopal, John Mascarenhas
openaire   +3 more sources

Correlation of cytogenetics and grade of bone marrow fibrosis in primary myelofibrosis [PDF]

open access: yesSrpski Medicinski Časopis Lekarske Komore
Introduction/Aim: Primary myelofibrosis is a clonal myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis.
Đorđević Vesna   +5 more
doaj   +1 more source

Primary Hypertrophic Osteoarthropathy With Myelofibrosis

open access: yesCureus, 2022
Primary hypertrophic osteoarthropathy (PHO) is a rare autosomal recessive inherited multi-system disorder characterized by a triad of pachydermia, periostosis, and clubbing. PHO was revealed to be caused by the HPGD gene producing 15-prostaglandin dehydrogenase and the SLCO2A1 gene expressing one kind of prostaglandin transporter.
Yousaf, Muhammad   +4 more
openaire   +2 more sources

Primary Myelofibrosis with Mesenteric Extramedullary Haematopoiesis [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2018
Primary myelofibrosis or chronic idiopathic myelofibrosis is a myeloproliferative neoplasm characterized by proliferation of abnormal haematopoietic stem cells in bone marrow resulting in replacement of marrow with fibrotic scar tissue.
Saurabh Kumar   +4 more
doaj   +1 more source

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]

open access: yes, 2019
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Annunziata, M.   +14 more
core   +1 more source

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression

open access: yesFrontiers in Oncology, 2022
In primary myelofibrosis, extra-domain A fibronectin (EDA-FN), the result of alternative splicing of FN gene, sustains megakaryocyte proliferation and confers a pro-inflammatory phenotype to bone marrow cell niches. In this work we assessed the levels of
Alessandro Malara   +6 more
doaj   +1 more source

Biology and Treatment of Primary Myelofibrosis [PDF]

open access: yesHematology, 2007
Abstract Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder associated with an average survival of less than 5 years. Therapy for PMF has used chemotherapeutic agents, immunomodulatory drugs, or biological-response modifiers that have not always been directed at the biological processes that underlie the origins of PMF.
Ronald Hoffman, Damiano Rondelli
openaire   +3 more sources

Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]

open access: yes, 2019
Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela   +1 more
core   +1 more source

Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2014
Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow ...
Cesar Cilento Ponce   +3 more
doaj   +1 more source

Targeted sequencing of candidate gene regions for myelofibrosis in dogs

open access: yesJournal of Veterinary Internal Medicine, 2022
Background Myelofibrosis often lacks an identifiable cause in dogs. In humans, most primary myelofibrosis cases develop secondary to driver mutations in JAK2, CALR, or MPL.
Amelia G. Campbell   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy